Abstract: Disclosed are recombinant bacteriophage constructs and related exogenous peptide sequences for generating immune responses against CD47. The disclosed recombinant phage constructs bind to antibodies against CD47 and can be administered to an animal to generate an immune response against CD47, including generating anti-CD47 antibodies. The disclosed recombinant phage may comprise an amino acid sequence of CD47, epitopic fragments, variants, or functional mimics thereof. Also disclosed are methods for making and selecting such recombinant phage constructs and compositions that comprise such constructs (e.g., compositions for inducing an immune response against CD47 including pharmaceutical or veterinary compositions used as vaccines). Also disclosed are recombinant polynucleotides comprising genomic nucleic acid of the recombinant phage constructs disclosed herein.

Abstract: Disclosed are recombinant bacteriophage constructs and related exogenous peptide sequences for generating immune responses against CD47. The disclosed recombinant phage constructs bind to antibodies against CD47 and can be administered to an animal to generate an immune response against CD47, including generating anti-CD47 antibodies. The disclosed recombinant phage may comprise an amino acid sequence of CD47, epitopic fragments, variants, or functional mimics thereof. Also disclosed are methods for making and selecting such recombinant phage constructs and compositions that comprise such constructs (e.g., compositions for inducing an immune response against CD47 including pharmaceutical or veterinary compositions used as vaccines). Also disclosed are recombinant polynucleotides comprising genomic nucleic acid of the recombinant phage constructs disclosed herein.

Abstract: Disclosed are recombinant bacteriophage constructs and related exogenous peptide sequences for generating immune responses against CD47. The disclosed recombinant phage constructs bind to antibodies against CD47 and can be administered to an animal to generate an immune response against CD47, including generating anti-CD47 antibodies. The disclosed recombinant phage may comprise an amino acid sequence of CD47, epitopic fragments, variants, or functional mimics thereof. Also disclosed are methods for making and selecting such recombinant phage constructs and compositions that comprise such constructs (e.g., compositions for inducing an immune response against CD47 including pharmaceutical or veterinary compositions used as vaccines). Also disclosed are recombinant polynucleotides comprising genomic nucleic acid of the recombinant phage constructs disclosed herein.

Abstract: Disclosed are methods, compositions, zona pellucida binding peptides and polypeptides, and expression vectors for use in species-specific immunocontraception of animals, which include landscape bacteriophage. The disclosed compositions may include immunogenic compositions or vaccines.

Abstract: Disclosed are recombinant bacteriophage constructs and related heterologous peptide sequences for contraception in animals. The disclosed recombinant phage constructs bind to antibodies against gonadotropin releasing hormone (GnRH) and can be administered to an animal to generate an immune response against GnRH, including generating anti-GnRH antibodies. The disclosed recombinant phage may comprise an amino acid sequence of gonadotropin releasing hormone (GnRH), epitopic fragments, variants, or functional mimics thereof. Also disclosed are methods for making and selecting such recombinant phage constructs and compositions that comprise such constructs (e.g., compositions for inducing an immune response against GnRH including pharmaceutical or veterinary compositions used as vaccines). Also disclosed are recombinant polynucleotides comprising genomic nucleic acid of the recombinant phage constructs disclosed herein.

Abstract: Disclosed are methods, compositions, zona pellucida binding peptides and polypeptides, and expression vectors for use in species-specific immunocontraception of animals, which include landscape bacteriophage. The disclosed compositions may include immunogenic compositions or vaccines.

Abstract: Compositions and methods for the isolation and manipulation of misfolded, or partially misfolded, proteins present in blood and other biological materials are provided. In one aspect of the invention, the compositions, hereinafter termed “proteons” are comprised of misfolded proteins. Also provided are compositions and methods for the isolation and manipulation of proteon nucleation centers (PNCs) upon which the proteons of the present in blood and other biological materials form. In another aspect of the invention, the PNCs are comprised of metallic nanoclusters.

Abstract: Compositions and methods for the isolation and manipulation of misfolded, or partially misfolded, proteins present in blood and other biological materials are provided. In one aspect of the invention, the compositions, hereinafter termed “proteons” are comprised of misfolded proteins. Also provided are compositions and methods for the isolation and manipulation of proteon nucleation centers (PNCs) upon which the proteons of the present in blood and other biological materials form. In another aspect of the invention, the PNCs are comprised of metallic nanoclusters.

Abstract: Compositions and methods for the isolation and manipulation of misfolded, or partially misfolded, proteins present in blood and other biological materials are provided. In one aspect of the invention, the compositions, hereinafter termed “proteons” are comprised of misfolded proteins. Also provided are compositions and methods for the isolation and manipulation of proteon nucleation centers (PNCs) upon which the proteons of the present in blood and other biological materials form. In another aspect of the invention, the PNCs are comprised of metallic nanoclusters.

Abstract: Methods and compositions for identifying and characterizing one or more ligands of a peptide are provided. In particular, the invention provides a phage ligand sensor device (PLSD) comprising a sensor coupled to a binding element of interest. Binding elements of interest comprise phage displaying at least one foreign peptide. The PLSD and assays find particular use in identifying and characterizing ligand-peptide interactions.

Abstract: Compositions and methods for the isolation and manipulation of misfolded, or partially misfolded, proteins present in blood and other biological materials are provided. In one aspect of the invention, the compositions, hereinafter termed “proteons” are comprised of misfolded proteins. Also provided are compositions and methods for the isolation and manipulation of proteon nucleation centers (PNCs) upon which the proteons of the present in blood and other biological materials form. In another aspect of the invention, the PNCs are comprised of metallic nanoclusters.

Abstract: Methods and compositions for evaluating the affinity of one or more ligands of interest are provided. In particular, a ligand sensor device (LSD) comprising a sensor coupled to a peptide of interest is provided. Assays using the LSD allow detection of ligand-peptide interactions directly in tissue samples and thus provide an in vitro assay to characterize peptide ligands. The LSD and assays find particular use in characterizing cell-specific peptides isolated from in vivo screening in animals to determine their suitability for use in human therapy.

Abstract: Compositions and methods for the isolation and manipulation of misfolded, or partially misfolded, proteins present in blood and other biological materials are provided. In one aspect of the invention, the compositions, hereinafter termed “proteons” are comprised of misfolded proteins. Also provided are compositions and methods for the isolation and manipulation of proteon nucleation centers (PNCs) upon which the proteons of the present in blood and other biological materials form. In another aspect of the invention, the PNCs are comprised of metallic nanoclusters.

Abstract: Methods and compositions for identifying and characterizing one or more ligands of a peptide are provided. In particular, the invention provides a phage ligand sensor device (PLSD) comprising a sensor coupled to a binding element of interest. Binding elements of interest comprise phage displaying at least one foreign peptide. The PLSD and assays find particular use in identifying and characterizing ligand-peptide interactions.

Abstract: Methods and compositions for evaluating the affinity of one or more ligands of interest are provided. In particular, a ligand sensor device (LSD) comprising a sensor coupled to a peptide of interest is provided. Assays using the LSD allow detection of ligand-peptide interactions directly in tissue samples and thus provide an in vitro assay to characterize peptide ligands. The LSD and assays find particular use in characterizing cell-specific peptides isolated from in vivo screening in animals to determine their suitability for use in human therapy.